Over the past 12 months, 3 insiders at AbCellera Biologics Inc. filed 5 open-market SEC Form 4 transactions on ABCL: 5 purchases worth $1.1M and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on May 14, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 14, 26 | John S. Montalbano | BUY | 20.0K | $4.77 | $95K |
| Feb 27, 26 | Andrew BoothChief Financial Officer | BUY | 42.6K | $3.42 | $146K |
| Feb 27, 26 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 38.0K | $3.44 | $131K |
| Feb 26, 26 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 177.5K | $3.27 | $580K |
| Nov 26, 25 | John S. MontalbanoDirector | BUY | 50.0K | $3.57 | $179K |
| Mar 11, 25 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 343.6K | $2.16 | $742K |
| Mar 10, 25 | John S. MontalbanoDirector | BUY | 25.0K | $2.30 | $58K |
| Mar 6, 25 | John S. MontalbanoDirector | BUY | 60.0K | $2.34 | $140K |
| Aug 29, 24 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 283.5K | $2.61 | $740K |
| Nov 8, 23 | John S. MontalbanoDirector | BUY | 10.0K | $4.46 | $45K |
| Nov 6, 23 | John S. MontalbanoDirector | BUY | 20.0K | $4.64 | $93K |
| Sep 22, 23 | Michael R HaydenDirector | BUY | 20.0K | $4.91 | $98K |
| Sep 12, 23 | Veronique LecaultChief Operating Officer | BUY | 20.0K | $5.19 | $104K |
| Aug 8, 23 | Michael R HaydenDirector | BUY | 30.0K | $5.90 | $177K |
| May 26, 23 | Andrew BoothChief Financial Officer | BUY | 14.5K | $6.85 | $99K |
| May 26, 23 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 153.0K | $6.52 | $998K |
| Dec 16, 22 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 85.1K | $10.10 | $860K |
| Aug 19, 22 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 200.0K | $11.46 | $2.3M |
| Jun 14, 22 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 9.2K | $8.05 | $74K |
| Jun 13, 22 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 54.9K | $8.03 | $441K |
| Jun 6, 22 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 64.5K | $7.50 | $484K |
| May 16, 22 | Veronique LecaultChief Operating Officer | BUY | 200.0K | $6.34 | $1.3M |
| May 13, 22 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 300.0K | $7.26 | $2.2M |
| May 12, 22 | Andrew BoothChief Financial Officer | BUY | 85.0K | $5.79 | $492K |
| May 12, 22 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 1.41M | $6.41 | $9.0M |
| Mar 4, 22 | John S. MontalbanoDirector | BUY | 10.0K | $8.54 | $85K |
| Mar 1, 22 | John S. MontalbanoDirector | BUY | 20.0K | $9.05 | $181K |
| Feb 28, 22 | Veronique LecaultChief Operating Officer | BUY | 230.8K | $8.66 | $2.0M |
| Dec 3, 21 | Andrew LoDirector | BUY | 86.9K | $14.02 | $1.2M |
| Nov 11, 21 | Andrew BoothChief Financial Officer | BUY | 53.5K | $14.74 | $789K |
| Nov 11, 21 | Thermopylae Holdings Ltd.TenPercentOwner | BUY | 203.0K | $14.76 | $3.0M |
| Sep 1, 21 | John HamerDirector | SELL | 137.4K | $16.93 | $2.3M |
| Aug 31, 21 | John HamerDirector | SELL | 162.6K | $16.95 | $2.8M |
| Aug 16, 21 | John S. MontalbanoDirector | BUY | 6.0K | $17.23 | $103K |
Over the past 12 months, insiders at AbCellera Biologics Inc. filed 5 open-market purchases worth $1.1M and 0 sales worth $0 on ABCL, which makes them net buyers over the period. The most recent Form 4 was filed on May 14, 26.
The largest recent open-market ABCL insider purchase in our data was $9.0M by Thermopylae Holdings Ltd., TenPercentOwner, filed on May 12, 22.
3 different insiders at AbCellera Biologics Inc. filed open-market SEC Form 4 transactions on ABCL over the last 12 months.
InsiderTape plots every ABCL insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every AbCellera Biologics Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →